\* \* \* Effective February 20, 2003

Danielson, CT, Danielson, RNAV (GPS) Rwy 31, Orig (CANCELLED)

Huntington, IN, Huntington Muni, VOR/ DME–A, Amdt 1

Huntington, IN, Huntington Muni, NDB RWY 9, Amdt 1

Huntington, IN, Huntington Muni, RNAV (GPS) RWY 9, Orig

Huntington, IN, Huntington Muni, RNAV (GPS) RWY 27, Orig

Huntington, IN, Huntington Muni, GPS RWY 9, Amdt 1, (CANCELLED)

Huntington, IN, Huntington Muni, GPS RWY 27, Orig, (CANCELLED)

Wichita, KS, Beech Factory, RNAV (GPS) Rwy 18, Orig (CANCELLED)

Wichita, KS, Beech Factory, RNAV (GPS) Rwy 36, Orig

Wichita, KS, Beech Factory, RNAV (GPS) Rwy 18, Orig

Wichita, KS, Beech Factory, GPS Rwy 36, Orig (CANCELLED)

Leesville, LA, Leesville, NDB RWY 36, Amdt 1

Leesville, LA, Leesville, RNAV (GPS) RWY 36, Orig

Owosso, MI, Owosso Community, RNAV (GPS) RWY 10, Orig

Sikeston, MO, Sikeston Memorial Muni, NDB RWY 20, Amdt 8A (CANCELLED)

Wichita Falls, TX, Sheppard AFB/Wichita Falls Muni, LOC BC RWY 15R, Amdt 11A (CANCELLED)

Lake Geneva, WI, Grand Geneva Resort, RNAV (GPS) RWY 23, Orig

[FR Doc. 03–650 Filed 1–14–03; 8:45 am] **BILLING CODE 4910–13–M** 

#### **DEPARTMENT OF ENERGY**

# Federal Energy Regulatory Commission

# 18 CFR part 390

[Docket No. RM02-10-000; Order No. 891]

## **Electronic Registration**

December 20, 2002.

**AGENCY:** Federal Energy Regulatory

Commission.

**ACTION:** Notice of extension of effective

date.

**SUMMARY:** The Federal Energy Regulatory Commission is extending the effective date of its requirement that users of its online applications register electronically. This extension is necessary because the eRegistration system will not be sufficiently implemented by the original effective date of January 7, 2003.

# FOR FURTHER INFORMATION CONTACT:

Christopher Cook (information technology advisor), Office of the Chief Information Officer, Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, (202) 502–8102. Wilbur Miller (legal advisor), Office of General Counsel, Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, (202) 502–8953.

1. On August 5, 2002, the Commission issued Order No. 891, establishing a system of electronic registration to act as a gateway to its online services. The eRegistration system will allow users to input identifying information only once as a precursor to using services such as electronic filing, electronic subscription, or electronic service. The registration system has been available on the Commission's web site, <a href="http://www.ferc.gov">http://www.ferc.gov</a>, since September as a voluntary system. Order No. 891 provided that eRegistration would become mandatory on January 7, 2003.<sup>2</sup>

2. Currently, eRegistration is not fully integrated with the online services with which it will operate, and this was expected to be the case on the original effective date. The Commission thus will extend the effective date until adequate integration is achieved. Once the system is ready, the Secretary of the Commission will issue a notice of the time when the eRegistration requirement will become effective. In the interim, eRegistration may be a prerequisite for the use of some informational services, such as electronic subscription.

The Commission orders: The effective date of 18 CFR 390.1 is extended until the new effective date is announced by the Secretary.

By the Commission.

# Magalie R. Salas,

Secretary.

[FR Doc. 03–834 Filed 1–14–03; 8:45 am]

BILLING CODE 6717-01-P

#### **DEPARTMENT OF JUSTICE**

#### **Drug Enforcement Administration**

#### 21 CFR Part 1308

[DEA-2361

## Schedules of Controlled Substances: Exempt Anabolic Steroid Products

**AGENCY:** Drug Enforcement Administration (DEA), Department of Justice.

**ACTION:** Interim rule and request for comments.

**SUMMARY:** The Drug Enforcement Administration (DEA) is designating

two pharmaceutical preparations as exempt anabolic steriod products under the Controlled Substances Act. This action is part of the ongoing implementation of the Anabolic Steriod Control Act of 1990.

DATES: Effective date: January 15, 2003. Comment date: Comments must be received on or before March 17, 2003.

ADDRESSES: Comments must be submitted to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537. Attention: DEA Federal Register Representative/CCR.

#### FOR FURTHER INFORMATION CONTACT:

Frank Sapienza, Chief, Drug and Chemical Evaluation Section, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Telephone: (202) 307–7183.

## SUPPLEMENTARY INFORMATION:

## **Background**

The Anabolic Steroids Control Act (ASCA) of 1990 (title XIX of Pub. L. 101-647) placed anabolic steroids into schedule III of the Controlled Substances Act (CSA) (21 U.S.C. 801 et seq.). Section 1903 of the ASCA provides that the Attorney General may exempt products which contain anabolic steroids from all or any part of the Controlled Substances Act (CSA) (21 U.S.C. 801 et seq.) if the products have no significant potential for abuse. The authority to exempt these products was delegated from the Attorney general to the Administrator of the Drug Enforcement Administration (28 CFR 0.1009b)), who, in turn, redelegated this authority to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration (28 CFR appendix to subpart R, section 7, paragraph (g)). The procedure for implementing this section of the ASCA is found in § 1308.33 of title 21 of the Code of Federal Regulations. An application which was in conformance with § 1308.33 of title 21 of the Code of Federal regulations was received and was forwarded to the Secretary of Health and Human Services for his evaluation. The purpose of this rule is to identify two products which the Deputy Assistant Administrator, Office of Diversion Control, finds meet the exempt anabolic steroid product criteria.

Anabolic Steroid Products Being Added to the List of Products Exempted From Application of the CSA

DEA received a letter dated June 18, 2002, written tot he DEA on behalf of Syntho Pharmaceuticals Inc., and two

<sup>&</sup>lt;sup>1</sup> See 18 CFR part 390 (2001).

<sup>&</sup>lt;sup>2</sup> FERC Stats. & Regs. ¶ 31,132, at p. 30,195 (2002), codifying requirement at 18 CFR § 390.1.